March 21, 2024

Texas Health and Human Services Commission
Submitted via email to MCDMedicalBenefitsPolicyComment@hhsc.state.tx.us

Re: Comment on Proposed Changes to the Texas Medicaid Limitations and Exclusions (Line 2.36)

On behalf of Whitman-Walker Institute, the United States Professional Association for Transgender Health (USPATH), and GLMA: Health Professionals Advancing LGBTQ+ Equality, we write in response to the proposed change to the Texas Medicaid Limitations and Exclusions. This change would add a new exclusion, in Line 2.36, that prohibits coverage for “Prescription medications and surgical procedures used for the purposes of transitioning biological sex, including sex change operations as listed in 2.63, except when provided to individuals with a medically verifiable genetic disorder of sex development.” Our organizations, which are comprised of medical experts and researchers with many years of experience in transgender health, strongly oppose this proposed change because it will impose discriminatory and medically unsound barriers for transgender Texas Medicaid beneficiaries seeking medically necessary treatment for gender dysphoria under the care of Texas clinicians. We urge the Texas Health and Human Services Commission to fully rescind this proposed change and to leave clinical decisions to patients, their parents and guardians, and their doctors.

About Whitman-Walker Institute and Our Expertise

As a community health system with more than 50 years of service to diverse patient populations, including thousands of transgender people, Whitman-Walker knows from experience that transgender people thrive when they are supported in who they are and have access to the medically necessary care they need. Whitman-Walker Institute, as the research, policy, and education arm of Whitman-Walker, conducts rigorous research and develops evidence-based policies that reflect the scientific literature and medical expertise of healthcare professionals who provide care to transgender patients. The Institute works closely with hospitals, clinics, and independent healthcare providers; transgender patients and families; and community-based social services organizations across Texas.

About USPATH and Our Expertise

As a chapter of the World Professional Association for Transgender Health (WPATH), which creates and disseminates the Standards of Care for the Health of Transgender and Gender Diverse People, USPATH provides a mechanism for professionals in the U.S. from disciplines such as medicine, mental and behavioral health, and the law to share research, clinical practice, and expertise on issues affecting the health and well-being of transgender people. USPATH encourages the dissemination of knowledge and best practice guidelines regarding transgender health and well-being in general to professionals and to the public. USPATH members and leadership are involved in providing medically necessary care for transgender persons, conducting rigorous research to understand the needs of transgender persons, and publishing peer-reviewed research.

About GLMA and Our Expertise
GLMA: Health Professionals Advancing LGBTQ+ Equality (“GLMA”), the largest and oldest association of LGBTQ+ and allied health professionals, is a national organization committed to ensuring health equity for LGBTQ+ communities and equality for LGBTQ+ health professionals in their work and learning environments. To achieve this mission, GLMA utilizes the scientific expertise of its diverse multidisciplinary membership to inform and drive advocacy, education, and research.

Scientific Evidence Demonstrates that Treatment for Gender Dysphoria is Safe, Effective, and Medically Necessary for Transgender People

Health care to treat gender dysphoria is medically necessary, evidence-based care provided to transgender people to alleviate the clinically significant psychological distress associated with an incongruence between an individual’s gender and their sex assigned at birth. Gender dysphoria is recognized as a serious medical condition by every major U.S. medical association and the World Health Organization. Every major medical and mental health professional association in the U.S. — representing more than 1.3 million U.S. doctors — supports individualized, age-appropriate treatment for gender dysphoria to promote the health and well-being of transgender people.¹

A robust body of evidence compiled over the last 50 years has demonstrated that mental health counseling combined with hormone therapy is safe, effective, and medically necessary to alleviate the negative health consequences of untreated gender dysphoria among transgender people. For example, research has shown that receipt of treatment that includes mental health counseling and hormone therapy among transgender young people (aged 13 to 20) was associated with 60% lower odds of depression and 73% lower odds of suicidality.² Other studies have found similar positive impacts³,⁴ on the mental health of transgender youth, including a nearly 40% lower odds of having a suicide attempt in the past year when transgender youth have access to hormone therapy under the care of a clinician.⁵ For transgender adults, treatment for gender dysphoria is associated with reduced rates of suicide attempts, anxiety, and depression, along with higher levels of life satisfaction, happiness, and quality of life.⁶⁷ In an appendix to this comment, we provide an annotated bibliography of these and dozens of other studies assessing treatment for gender dysphoria. The proposed rule change contradicts this evidence base by introducing a discriminatory and medically unsound restriction that will ban access to best-practice, medically necessary care for transgender Medicaid beneficiaries, exacerbating the

distress caused by untreated gender dysphoria and negatively impacting these patients’ health and well-being.

Evidence-Based Clinical Standards Guide the Provision of Coverage and Treatment for Gender Dysphoria

In the U.S., individualized, age-appropriate care is provided to transgender people by licensed medical professionals according to expert standards of clinical care that have been in place for decades, such as those maintained by WPATH8 and the Endocrine Society.9 The WPATH Standards have been continuously maintained for more than four decades, and the most recent edition (Version 8, released in 2022) is based on dozens of independent systematic reviews and a consensus-based expert review process involving more than 100 experts from around the world. These standards ensure that decision-making about health care for transgender people is guided by multi-disciplinary care teams of medical and mental health professionals working together with patients and, for minors, with their parents, to assess and meet the patient’s medical needs. This enables health professionals to help transgender patients navigate safe and effective pathways to care that maximizes their physical and psychological well-being. We stand firmly behind the robust evidence base and expert clinical guidelines that demonstrate this care is safe, effective, and medically necessary for transgender people to thrive. The proposed rule change undermines these long-standing expert clinical standards and represents governmental intrusion into the practice of medicine, as well as the privacy and sanctity of the relationship between medical professionals, patients, and parents.

The Proposed Exclusion Is Contrary to Every Major Trend in Coverage for Gender Dysphoria

The first U.S. clinics opened to provide treatment for gender dysphoria to transgender individuals in the 1960s and 1970s, and the first edition of the WPATH Standards of Care was published in 1979.10 By the late 1970s, nationwide trends favored insurance coverage for treatment of gender dysphoria, particularly through state Medicaid programs.

In California, for instance, courts found in J.D. v. Lackner and G.B. v. Lackner, a pair of cases decided in 1978 regarding Medi-Cal coverage of vaginoplasty for transgender women, that the plaintiff “has an illness and...as far as her illness affects her, the proposed surgery is medically reasonable and necessary and...there is no other effective treatment method.”11 The judges further asserted that “the proposed surgery is medically reasonable and necessary” and that “we do not believe, by the wildest stretch of the imagination, that such surgery can reasonably and logically be characterized as cosmetic.”12

In 1980, the Eighth Circuit ruled in Pinneke v. Preisser that Iowa’s Medicaid program had, by excluding coverage of treatment for gender dysphoria, made an “arbitrary denial of benefits based solely on the ‘diagnosis, type of illness, or condition’” and that this denial was “not consistent with the objectives

of the Medicaid statute” or with a longstanding Medicaid regulation that prohibits states from “arbitrarily deny[ing] or reduc[ing] the amount, duration, or scope of a required service under [the Medicaid statute] to an otherwise eligible beneficiary solely because of the diagnosis, type of illness, or condition.”13 The court in Pinneke further noted that “(t)he decision of whether or not certain treatment or a particular type of surgery is ‘medically necessary’ rests with the individual recipient’s physician and not with clerical personnel or government officials.”

In Doe v. State (1977), the Minnesota Supreme Court similarly found that Minnesota’s Medicaid program had discriminated against a transgender woman on the basis of her diagnosis because the vaginoplasty for which she sought coverage was “the only surgical treatment which, if recommended by a physician and related to a patient’s health, is not covered by the program.”14

In Cruz v. Zucker (2016), which struck down a ban on New York State Medicaid coverage for gender dysphoria treatment, the court ruled that “a state cannot say ‘never’ when it comes to medically necessary treatments, because there are no such reasons justifying categorical bans on medically necessary treatment. A categorical ban on medically necessary treatment for a specific diagnosis would not adequately…meet the needs of the Medicaid population of the state.”15

In Flack v. Wisconsin Department of Health Services (2019), the court similarly ruled against the state Medicaid program’s exclusion, finding that “the medical consensus is that gender-confirming treatment, including surgery, is accepted, safe, and effective in the treatment of gender dysphoria, meaning that the denial of Medicaid benefits for needed medical treatment completely fails to protect the public health.”16

As of early 2024, the overwhelming majority of states do not exclude coverage of gender-affirming care from Medicaid, and 27 states and D.C. explicitly affirm and affirmatively delineate coverage of a range of treatments for gender dysphoria.17 Some states are continuing to explicitly broaden and clarify the scope of Medicaid coverage for this condition. In Washington State, for instance, recent legislation codified that the state’s Medicaid program covers a range of “surgical and ancillary services,” as well as puberty-delaying medications, for transgender people.18 The legislation indicates that the list of covered services is not exhaustive and requires that a “health care provider with experience prescribing and/or delivering gender affirming treatment must review and confirm the appropriateness of any adverse benefit determination.19

These coverage dynamics in state Medicaid programs parallel those in private state-regulated plans, employer-sponsored coverage, the Federal Employees Health Benefits (FEHB) Program, and the federal Medicare Program. In 2022, for instance, 21 state insurance commissioners wrote a joint letter to the U.S. Department of Health and Human Services (HHS) stating, “Transgender people should have equal access to the same health insurance and care as every other insured American. This includes

13 Pinneke v. Preisser, 623 F.2d 546 (8th Cir. 1980)
14 Doe v. State, Dept. of Public Welfare, 257 N.W.2d 816 (Minn. 1977)
16 Flack v. Wis. Dep’t of Health Servs., 395 F. Supp. 3d 1001 (W.D. Wis. 2019)
health care related to gender affirmation, which for years has been recognized by every major U.S. medical society as effective and medically necessary for many individuals.\textsuperscript{20}

In addition to state regulators, insurance carriers themselves have also spoken strongly about their interest in ensuring that transgender enrollees can access treatment for gender dysphoria. In 2022, America’s Health Insurance Plans (AHIP), the professional trade association that represents 1,300 member companies that sell health insurance coverage for more than 200 million people nationwide, wrote in a letter to HHS that they “strongly support ensuring that appropriate gender-affirming care is available and accessible to enrollees. We [are committed] to ensuring benefit designs and coverage decisions reflect evidence-based guidelines and recommendations and do not restrict coverage related to gender identity.”\textsuperscript{21}

Among state employee benefit plans, more than 40 states and territories do not have categorical transgender-specific exclusions in their plans; of these, 24 states and D.C. affirmatively spell out the gender-affirming services that their state employee plans cover.\textsuperscript{22}

Similarly, according to the Corporate Equality Index (CEI), which has tracked the status of private employer-sponsored coverage for treatment of gender dysphoria since 2002, 67 percent of the entire Fortune 500—and 86 percent of all CEI-rated businesses (1,088 of 1,271)—offered employee benefits with no transgender-specific exclusions in 2022.\textsuperscript{23} In 2015, 54 percent (421 of 781) companies offered at least one fully inclusive plan to their employees, and by 2022 that number had reached 91 percent (1,160 out of 1,271).

In 2016, the White House Office of Personnel Management (OPM) required all carriers participating in the FEHB program to remove blanket exclusions of services, drugs, or supplies related to the treatment of gender dysphoria. For plan year 2023, OPM instituted the following requirements for FEHB carriers:\textsuperscript{24}

\begin{itemize}
\item[a.] Have adopted one or more recognized entities in order to guide evidence-based benefits coverage and medical policies pertaining to gender affirming care and services, such as the World Professional Association of Transgender Health (WPATH) Standards of Care, the Endocrine Society, and the Fenway Institute. These entities provide evidence-based clinical guidelines for health professionals to assist transgender and gender diverse people with safe and effective pathways that maximize their overall health, including physical and psychological well-being.
\item[b.] Will provide individuals diagnosed with and/or undergoing evaluation for gender dysphoria the option to use a Care Coordinator to assist and support them as they seek...
\end{itemize}

gender-affirming care and services. If network providers are not available to provide medically necessary treatment of gender dysphoria, FEHB Carriers will provide members direction on how to find qualified providers with experience delivering this specialized care.

c. Have reviewed their formularies to ensure that transgender and gender diverse individuals have equitable access to medications and provide coverage of medically necessary hormonal therapies for gender transition care.

In 2014, the HHS Departmental Appeals Board (DAB) struck down Medicare’s 1989 ban on coverage of treatment for gender dysphoria, finding that the exclusion was invalid on the grounds that it was based on outdated evidence that was not complete or adequate to support the determination that this treatment was never medically necessary. In its ruling, the DAB rejected the assertion that gender-affirming surgeries are “experimental” and “controversial,” finding instead that current evidence “indicates a consensus among researchers and mainstream medical organizations that transsexual surgery is an effective, safe and medically necessary treatment for transsexualism.”

Following the rescinding of the exclusion, Medicare covers surgeries and other gender-affirming care for transgender individuals according to individual assessments of medical necessity.

An example of this coverage policy in practice is a 2016 ruling by the Medicare Appeals Council (“the Council”), which is part of the DAB, finding that a Medicare Advantage plan’s decision to deny coverage for gender-affirming surgery to a transgender Medicare beneficiary did not comport with Medicare’s statutory “reasonable and necessary” coverage criterion. The Council asserted that the WPATH Standards of Care are “reasonable guidelines to determine medical necessity” and found that, inasmuch as the enrollee “satisfies all of the WPATH clinical requirements for gender reassignment surgery…the requested vaginoplasty is medically reasonable and necessary for treatment of this enrollee’s gender dysphoria under Section 1862(a)(1)(A) of the [Social Security] Act and is covered under existing [Centers for Medicare & Medicaid Services] guidance.”

The Proposed Exclusion Does Not Reflect Cost-Effective Approaches to the Treatment of Gender Dysphoria

Evidence indicates that insurance coverage of treatment for gender dysphoria is low-cost and highly cost-effective. The impact of gender-affirming care on payer budgets has remained nominal even as coverage has become more available, standardized, and routine. A California Department of Insurance assessment of a state law that broadly prohibited insurance discrimination against transgender beneficiaries, for instance, showed that a major state university-sponsored plan had a utilization rate of only 0.062 per 1,000 covered persons for this care over the 6.5 years following the law’s enactment; across the state, impacts on premium costs were “immaterial,” leading the Department to conclude that “the benefits of eliminating discrimination far exceed the insignificant costs.”

A 2016 economic model evaluating the cost-effectiveness of care for transgender people that included hormone therapy and surgical procedures underscores this conclusion, finding that the incremental

---


cost-effectiveness ratio of these services was less than $8,000 per quality-adjusted life year (QALY) gained over a ten-year time horizon.\(^{28}\) This is far below a typical U.S. “willingness to pay” threshold of $100,000 per QALY.\(^{29}\) This study also found that, on a per member per month (PMPM) basis, coverage of surgical and other services for transgender men and women together cost $0.016.

Similar research indicates that each covered transgender person in a major national commercial insurance database incurr an average of less than $1,800 in costs per year for hormone therapy (including puberty delay medications) and surgeries (including facial surgeries) combined to treat gender dysphoria.\(^{30}\) Considered on a PMPM basis, the budget impact of covering this care was $0.73 per year, or $0.06 PMPM. Similarly, an actuarial assessment conducted for the North Carolina State Health Plan estimated a PMPM cost range of $0.06-$0.15 (0.011% to 0.027% of premiums).\(^{31}\)

Estimates from other states show equally low utilization and related low costs, with Alaska estimating that coverage for gender dysphoria would result in increases of 0.03% to 0.04% of total costs for its state employee plan\(^{32}\) and Wisconsin noting costs to its state employee plan are “inmaterial, since it represents less than 0.1% of the overall costs of medical care.”\(^{33}\) Cost estimates of coverage for gender-affirming care under Wisconsin Medicaid were “actuarially immaterial, as they are equal to approximately 0.008% to 0.03%” of Wisconsin’s share of its Medicaid budget.\(^{34}\) An analysis in the military context concluded that the cost of covering gender-affirming care was “too low to matter”\(^{35}\) or, as military leadership noted, “‘budget dust,’ hardly even a rounding error.”\(^{36}\)

Overall, the actuarial evidence indicates that gender-affirming care is not expensive when considered from a payer or societal perspective, but it can easily be beyond the individual reach of transgender people, particularly those who rely on public coverage programs such as Medicaid.

**The Proposed Exclusion Is Illegal and Will Cost Texas Taxpayers in the Courts**

Federal law has a strong interest in protecting access to medically necessary, clinician-prescribed care through the Medicaid program. The treatments at issue in the proposed rule change—prescription medications and surgical procedures—remain covered except in the case of transgender individuals.

---


Federal courts considering similar restrictions in state Medicaid programs over the last several years have found that such exclusions are discriminatory and in violation of the Medicaid Statute itself, Section 1557 of the Affordable Care Act, and the Equal Protection Clause of the U.S. Constitution.\textsuperscript{37,38} The proposed exclusion in Texas Medicaid regulations is quite clearly in violation of all of these federal statutes. If Texas proceeds with the proposed rule change, it can expect a swift legal challenge that will waste precious taxpayer resources in a protracted legal battle.

**Conclusion**

The proposed rule change in Line 2.36 of the Texas Medicaid Limitations and Exclusions takes complex, individualized medical decision-making out of the hands of medical professionals and their patients. It disregards the science and widely accepted clinical standards of care and infringes on the ability of Texas Medicaid beneficiaries to access medically necessary care endorsed by every legitimate U.S. medical professional association and provided in an individualized, age-appropriate manner by licensed clinicians.

We firmly believe this proposed rule change is an unwarranted government intrusion into the practice of medicine. It will violate the rights and harm the well-being of transgender individuals of all ages seeking medically necessary healthcare, and it imposes unconscionable and illegal restrictions that should have no place in Texas, particularly in a program that provides vital coverage and care for low-income Texans. Whitman-Walker Institute, GLMA: Health Professionals Advancing LGBTQ+ Equality, and the U.S. Professional Association for Transgender Health strongly oppose the proposed rule change and urge the Texas Health and Human Services Commission to rescind it in full.

Thank you for your consideration of these comments.

Kellan E. Baker, PhD, MPH, MA  
Executive Director  
Whitman-Walker Institute

Carl G. Streed, Jr., MD, MPH, FACP, FAHA  
President  
US Professional Association for Transgender Health

Alex Sheldon  
Executive Director  
GLMA: Health Professionals Advancing LGBTQ+ Equality

\textsuperscript{37} Dekker v. Weida, 4:22cv325-RH-MAF (N.D. Fla. Jun. 21, 2023)  
\textsuperscript{38} Fain v. Crouch, 540 F. Supp. 3d 575 (S.D.W. Va. 2021)
A strong and well-established body of evidence, developed over decades, demonstrates that individualized and age-appropriate medical care for transgender people improves mental health and overall well-being. The positive effects of this care include decreases in depression, anxiety, and suicidal ideation, as well as improvements in quality of life and body satisfaction. These peer-reviewed research studies and systematic reviews have been published in well-respected journals such as the New England Journal of Medicine, Journal of Adolescent Health, Pediatrics, and The Lancet.

**TOP RESEARCH STUDIES**


   **Summary:** Gender-affirming hormone therapy (GAH) for transgender adolescents (8% had also had previous puberty-delay medications) improved appearance congruence (the feeling that their body matches their gender), positive affect, and life satisfaction. It also decreased depression and anxiety symptoms. These improvements were sustained over a period of 2 years and are consistent with those of other longitudinal studies involving transgender youth receiving GAH.


   **Summary:** Transgender and gender diverse adults seeking testosterone therapy were randomly divided into two groups: those who started treatment right away and those who waited three months before initiation. Transgender individuals who had immediate access to hormone therapy saw significant decreases in gender dysphoria, depression, and suicidality compared to individuals who had to wait three months for treatment. Furthermore, among individuals experiencing suicidality at the start of the study, 52% of those with immediate treatment access reported their suicidality resolved, compared to only 5% of individuals who waited three months for treatment.


   **Summary:** Transgender and non-binary youth who were followed for one year had lower odds of depression and suicidality after receiving puberty delay medications and/or hormone therapy. Specifically, the study observed 60% lower odds of depression (adjusted odds ratio [aOR], 0.40; 95% CI, 0.17-0.95) and 73% lower odds of suicidality (aOR, 0.27; 95% CI, 0.11-0.65) among youths who had initiated puberty delay medications or hormone therapy compared with youths who had not.

**Summary:** At baseline, adolescents with gender dysphoria (GD) showed poor functioning. GD adolescents’ global functioning improved significantly after 6 months of psychological support (p < 0.001). GD adolescents also receiving puberty suppression had significantly better psychosocial functioning after 12 months of puberty delay medications, compared with when they had received only psychological support (p = 0.001).


**Summary:** Transgender youth who had a chosen name that they could use freely in different environments—such as home, school, work, and with friends—reported fewer symptoms of depression, less suicidal ideation, and less suicidal behavior. Specifically, an increase by one context in which a chosen name could be used predicted a 5.37-unit decrease in depressive symptoms, a 29% decrease in suicidal ideation, and a 56% decrease in suicidal behavior. Depressive symptoms, suicidal ideation, and suicidal behavior were at the lowest levels when chosen names could be used in all four contexts.


**Summary:** Before medical treatment, transgender adolescents showed more internalizing problems and reported increased self-harm/suicidality and poorer peer relations compared with their age-equivalent peers. Transgender adolescents receiving puberty delay medications had fewer emotional and behavioral problems than the group that had just been referred to care and had similar or fewer problems than their same-age cisgender peers. Overall, transgender adolescents show poorer psychological well-being before treatment but show similar or better psychological functioning compared with cisgender peers from the general population after the start of specialized transgender care involving puberty suppression.

**FULL RESEARCH COMPILATION**

**MENTAL HEALTH**

Numerous research studies show that transgender young people are at risk for poorer mental health outcomes and that access to medically necessary care can improve mental health.

• Transgender adolescents and young adults who received treatment for gender dysphoria reported improved mental health and quality of life.


• Transgender youth who received hormone therapy saw a significant increase in overall well-being and a decrease in suicidality.


• Transgender individuals aged 15-35 who had chest surgery experienced improved gender and appearance congruence (the feeling that their body matches their gender) and reduced chest dysphoria.


• After one year of receiving hormone therapy, transgender adolescents reported significant decreases in depression, anxiety, and body dissatisfaction, along with significant improvements in quality of life.


• Treatment for transgender adolescents that included puberty delay medications improved appearance congruence (the feeling that their body matches their gender), positive affect, and life satisfaction, as well as decreasing depression and anxiety symptoms.


• Among more than 100 minors seen at a gender identity clinic in Spain between 1999 to 2016, 97.6% persisted in their transgender identity after a median follow-up time of 2.6 years.


• Puberty delay medications for young transgender people (aged 12-16) were associated with a decrease in behavioral and emotional problems and depressive symptoms, and general functioning improved significantly.


• Treatment starting in adolescence resulted in alleviated gender dysphoria and improved psychological functioning.


• Treatment for transgender young people (aged 16-25) was linked to less anxiety and depression.

- Testosterone treatment for transgender adolescent boys was associated with a significant decrease in anxiety and depression, as well as greater body satisfaction.

Green AE, DeChants JP, Price MN, & Davis CK. (2022). Association of Gender-Affirming Hormone Therapy with Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth. *Journal of Adolescent Health.*

- Transgender youth who received hormone therapy had lower odds of depression and suicidal thoughts compared to youth who wanted this care but did not receive it.
- For youth under 18, hormone therapy was associated with 40% lower odds of attempting suicide.


- Patients followed for more than three years saw significant decreases in psychological distress (including anxiety and depression) after receiving hormone therapy.
- Patients indicated they had a better mood and increased happiness after receiving treatment.


- This study of nearly 4,000 transgender adolescents found that, compared to their cisgender siblings, trans and gender diverse adolescents used more mental healthcare services, namely for anxiety, suicidal ideation, and mood, personality, and psychotic disorders.
- This indicates that ongoing mental health support, in addition to necessary medical treatments, are key to supporting the well-being of transgender young people.


- Suicidality among adolescents with gender dysphoria who received hormone therapy decreased from 35% to 4% (p<0.0001).


- Transgender adolescents experienced significant improvements in body dissatisfaction after receiving hormone therapy. Symptoms of depression and anxiety also decreased after receiving this care.


- Transgender adolescents who received puberty delay medications followed by hormone therapy experienced significant reductions of gender dysphoria and improvements in social skills (e.g., engaging and interacting with others). They also reported reductions in self-harm and suicidality.
• Caregivers of transgender adolescents observed a significant decrease in depressive and anxious behaviors one year after the adolescent began hormone therapy treatment.


• An analysis of survey data from more than 1,000 transgender people found that accessing medical care during adolescence significantly reduced severe psychological distress in adulthood.


• Transgender adults who were affirmed in their gender identity—including access to appropriate medical care—had lower odds of suicidal ideation and psychological distress.


• Transgender adolescents who received hormone treatment saw significant improvement in emotional symptoms, including less anxiety, depression, and emotional distress.


• In this randomized controlled trial of transgender and gender diverse adults seeking testosterone therapy, those who had immediate access to hormone therapy saw significant decreases in gender dysphoria, depression, and suicidality compared to individuals who had to wait three months for treatment.


• Among transgender and nonbinary adolescents, hormone therapy was associated with fewer anxiety symptoms; family support was associated with fewer depressive symptoms and nonsuicidal self-injury; and friend support was associated with fewer anxiety symptoms and less suicidality.


• Transgender and nonbinary youth who were followed for one year had lower odds of depression and suicidality after receiving treatment that included puberty delay medications or hormone therapy.


• In survey data from more than 20,000 transgender adults, those who received puberty delay medications had significantly lower odds of lifetime suicidal ideation when compared to transgender adults who wanted this treatment but were unable to obtain it.

- Analyzing data from more than 20,000 transgender adults, the study found that access to hormone therapy during adolescence was associated with lower odds of suicidal ideation in the past year compared to accessing hormone therapy during adulthood.


- Transgender adolescents who received puberty delay medications had fewer emotional and behavioral problems than their transgender peers who didn’t receive appropriate medical treatment.

**SOCIAL SUPPORT**

Numerous studies show that social support (e.g., allowing a young person to use their chosen name and pronouns) improves a range of health outcomes for transgender young people.


- In a study with transgender youth ages 11-17, affirming support from parents predicted fewer depressive symptoms. This included having parents that affirmed their gender identity socially, legally, and medically.
- Parents also cited laws as frequently delaying or controlling desired medical affirmation for their child.


- Unsupportive families are associated with a higher risk of suicide attempts and running away from home among transgender young people, whereas supportive family environments mitigate, and in some cases virtually eliminate, these risks.


- Adolescents with gender dysphoria showed significant improvements in psychosocial functioning after receiving psychological support from their families, doctors, and/or therapists.
- Adolescents experienced even further improvements in psychosocial functioning after receiving puberty delay medications.


- Transgender young people (aged 16-25) whose parents used their chosen name had fewer depression symptoms and less anxiety.
• Transgender young people who could not express their true gender had more anxiety and symptoms of depression.


• A survey of more than 100 pediatric endocrinologists providing care to transgender people found that nearly 60% were concerned about the risk of legal action/medical liability related to their practice.

• More than 25% of providers in states with a medical care ban expressed concerns for their personal safety in the work and/or home settings because of the gender-affirming care they provide.

Kuper LE, Adams N, & Mustanski BS. (2018). Exploring Cross-Sectional Predictors of Suicide Ideation, Attempt, and Risk in a Large Online Sample of Transgender and Gender Nonconforming Youth and Young Adults. *LGBT Health*.

• Friend and family support was associated with decreased suicide attempts and suicidal ideation among transgender youth and young adults (aged 14-30).


• Transgender children who were socially supported—including being able to express their gender identity in public and use their chosen pronouns—had mental health outcomes similar to their peers.


• 97.5% of transgender youth who were socially supported at early ages (median age: 8.1 years) continued to identify as transgender after 5 years.


• Low acceptance of transgender youths’ gender identity from their primary caregivers was associated with increased depressive and anxiety symptoms.

• Lower sibling acceptance of gender identity predicted increased suicidal ideation among transgender youth.

Russell ST, Pollitt AM, Li G, & Grossman AH. (2018). Chosen Name Use is Linked to Reduced Depressive Symptoms, Suicidal Ideation and Behavior among Transgender Youth. *Journal of Adolescent Health*.

• Transgender youth who had a chosen name that they could use freely in different environments—such as home, school, work, and with friends—reported fewer symptoms of depression, less suicidal ideation, and less suicidal behavior.


• In a study of 66 transgender youth and young adults (aged 12-24), parental support was significantly associated with higher life satisfaction and fewer depressive symptoms.
STUDIES REBUTTING DISINFORMATION

This section highlights research that rebuts common myths and disinformation about gender identity and transgender medical care for youth, such as myths of social contagion, impact on bone density, and persistence of gender dysphoria.


- A study of more than 150 transgender adolescents looked at whether those with more recent knowledge of their gender experienced different outcomes compared to adolescents who had known about their gender for longer. They found that more recent gender knowledge was not associated with symptoms of depression, psychological distress, neurodevelopmental disorders, self-harm, or symptoms of gender dysphoria.
- The study concluded that there is no empirical support for the concept of “rapid onset gender dysphoria.”


- A study that followed 12–15-year-olds with persistent and severe gender dysphoria who received puberty delay medications found no change in baseline in spine bone mineral density nor hip bone mineral density.
- No changes in psychological function were identified. Overall patient experiences of treatment on puberty delay medications were positive.


- Analyzed data from transgender youth (aged 12+) who initiated gender-affirming hormone therapy from 2000-2019. Of the 385 youth in the study, a little less than one-third started hormone therapy before their 18th birthday.
- Only six participants (1.6%) ultimately discontinued gender-affirming hormone therapy, and at least two patients later resumed receiving care. Reasons for discontinuing hormone therapy included financial barriers, bullying by peers, and experiencing a change in their gender identity.
- Only two patients permanently discontinued receiving hormone therapy, but reported not regretting initiating care because they found it was an important part of understanding their gender identity.


- Adolescents with gender dysphoria taking puberty delay medications showed no difference in executive brain function compared to adolescents with gender dysphoria who did not take puberty delay medications.

- Analyzed data from nearly 27,500 transgender adults who completed the 2015 US Transgender Survey and found that 40.8% reported they realized their gender identity later in life (i.e., 11 years or older).
- Among participants who realized their gender identity in childhood (10 years or younger), the median age at which they first told someone about their gender identity was 22 years old.


- In a study that followed more than 700 transgender young people in the Netherlands, 98% of those who started medical treatment in adolescence (specifically, puberty delay medications followed by hormone therapy) continued this treatment into adulthood.


- In a study of 75 transgender people who received puberty delay medications and hormone therapy, it was found that after 15 years of hormone use, bone density levels returned to pre-treatment (baseline) levels.

QUALITATIVE STUDIES

The studies in this section conducted interviews with transgender adolescents and parents to capture their experiences with providers and the health care system. This section also includes studies that interviewed health care providers and captured their experiences since the rise of anti-trans legislation.


- Transgender adolescents raised the importance of providers asking about their gender and pronouns to show caring and respect.


- Transgender adults described their desire for, and importance of, accessing care to alleviate their gender dysphoria and be recognized by society as the gender they know themselves to be. Accessing this care improved their mental health, and for many helped them recover from previous eating disorders.
- Several barriers prevent transgender adults from accessing the care they wanted, including (1) high financial costs for care and inadequate insurance coverage; (2) logistical barriers (i.e., lack of local providers, inability to take time off work); (3) personal fears about suboptimal outcomes; and (4) fears of societal discrimination, such as family rejection and job loss.

- Transgender youth and caregivers described barriers in accessing medically necessary care, including (1) few accessible pediatric providers are trained in transgender care; (2) lack of consistently applied protocols; (3) inconsistent use of chosen name/pronoun; (4) uncoordinated care and gatekeeping; (5) limited/delayed access to pubertal blockers and hormone therapy; and (6) insurance exclusions.


- Transgender adolescents and young adults described affirming care as having providers who correctly used their chosen name, respected them, took them seriously, and treated them “like a normal person.”


- In a survey of more than 100 medical and mental healthcare providers across the U.S., 70% shared that they, their practice, or their institution had received threats for delivering care to transgender patients.

- Providers described the impact of this targeted harassment on their physiological well-being and on their ability to deliver care to their patients.


- Surveyed 277 parents of gender diverse youth, nearly all of whom described the positive impact of transgender medical care on their child’s mental health.

- On experiences accessing care, some had to travel far distances to a clinic and experienced long wait times (e.g., 8 months). Many parents expressed relief in finding a gender-affirming care provider. “We felt like we were drowning, and the immediate support and medical care helped us catch our breath.” – Mother of a transgender son from Ohio

- Parents said that some providers threatened to report them to child protective services. Others had positive experiences with healthcare providers who created a safe and respectful space and worked closely with both the parents and the child.


- In a study of 176 transgender adolescents and young adults, the majority expressed interest in starting hormone therapy. A smaller percentage expressed interest in eventual surgery, and most of the participants with surgery did not want genital surgery.


- Clinicians described how almost all transgender adolescents suffer from (the anticipation of) the development of secondary sex characteristics that come with puberty. Most clinicians are aware that delaying or avoiding development of those changes through puberty delay medications would help reduce this suffering.
• Parents, clinicians, and adolescents stated that puberty delay medications give them time to think about whether they want to pursue next steps in medical care without worrying about irreversible changes.

REVIEWS
The studies in this section reviewed large numbers of research studies to draw overall conclusions about the established body of literature that demonstrates the benefits of this care for transgender people.


• A systematic review of 27 studies, pooling 7,928 transgender patients who underwent any type of surgery to treat gender dysphoria, found that the pooled prevalence of regret after these surgeries was 1%.


• A review of 15 articles published since 2011 found that transgender youth have higher rates of depression, suicidality and self-harm, and eating disorders when compared with their peers.

• Appropriate care and social support in childhood was associated with improved psychological functioning for gender-variant children and adolescents.


• A review of the scientific literature found that transgender youth who receive puberty delay medications experience either no change or a slight decrease in bone mineral density, and bone mineral density returns to baseline after starting hormone therapy.


• A review of 24 studies on social affirmation (e.g., family support) and legal affirmation (e.g., name or gender marker change) found positive relationships with several health outcomes. This included findings that social and legal affirmation was associated with fewer reports of depression, anxiety, PTD, and psychological distress.


• A review of the literature on the impact of puberty delay medications on transgender youth notes that psychiatric disorders have been shown to decrease in intensity after receipt of medical interventions. Studies have found significant reductions in depression and improvements in overall functioning.

• Notably, after receiving treatment for gender dysphoria, transgender youth become similar to their same-age non-transgender peers in quality of life, life satisfaction, and happiness.

- This analysis of the four principles of biomedical ethics and the body of research on gender-affirming care concludes that the provision of gender-affirming hormone therapy for transgender adolescents is ethically required and that restricting this care is ethically wrong. The analysis describes the literature as it pertains to 1) beneficence – the obligation to bring benefit to the person; 2) nonmaleficence – the obligation to avoid harm to the person; 3) autonomy – the obligation to respect the person’s right to self-determination; and 4) justice – the obligation to provide just treatment for the person.


- In a workshop featuring physicians, transgender youth, and their parents, it was noted the evidence-based guidelines for care set forth by organizations such as the American Academy of Pediatrics, The Endocrine Society, the American Society for Reproductive Medicine, and the World Professional Association for Transgender Health indicate that medical care alleviates gender dysphoria in a way that mental health care alone cannot address.


- A review of 11 studies found that the use of puberty delay medications improved mental health in transgender adolescents.


- A review of 53 studies found reduced rates of suicide attempts, anxiety, and depression among transgender adults after surgery to treat gender dysphoria.
- Findings also indicate higher levels of life satisfaction, happiness, and quality of life after surgery to treat gender dysphoria.

**OTHER HEALTH OUTCOMES**

*This section contains research that looked at the impact of care on other health outcomes and utilization of health services, including for transgender adults.*


- Transgender youth who could access treatment that included puberty delay medications or hormone therapy were more likely to have gotten tested for sexually transmitted diseases (STDs) and have heard about PrEP.
- Uptake and awareness of sexual health services is particularly important for transgender youth who are at disproportionately high risk for HIV and STDs.

Bruce L, Khouri AN, Bolze A, et al. (2023). *Long-Term Regret and Satisfaction with Decision Following Gender-Affirming Mastectomy.* *JAMA.*
In this cross-sectional study of 139 transgender survey respondents who underwent mastectomy in the past 30 years, the median satisfaction score was 5 on a 5-point scale, with higher scores indicating higher satisfaction. The median decisional regret score was 0 on a 100-point scale, with lower scores indicating lower levels of regret.

Additional commentary in JAMA: Low Rate of Regret After Gender-Affirming Mastectomy Highlights a Double Standard


This study analyzed survey data from more than 6,500 transgender individuals across the 27 European Union (EU) member states. In countries with more discriminatory laws against transgender people (e.g., requiring medical or surgical interventions to change one’s legal gender), transgender people were about 25% less likely to seek necessary medical care compared to countries with more inclusive laws and policies.


Black transgender youth (ages 16-24) who were not affirmed in the doctor’s office delayed or chose not to seek out health care. Affirmation included the use of the person’s pronouns in the doctor’s office and the ability of their doctor to provide resources that affirmed their gender identity.


A study of more than 200 transgender and gender diverse patients who had surgery to treat gender dysphoria (average age 31.8 years) found that surgery sustainably improved patients’ self-reported health, including gender dysphoria.


In a review of nearly 2,000 individuals who had surgery to treat gender dysphoria between 2016-2021, only 0.3% requested the surgery be reversed or transitioned back to their sex assigned at birth. This rate of regret is consistent with other evidence-based findings.


In a study of more than 3,000 adults with gender dysphoria who obtained gender-affirming surgery, there were significant decreases in depression, anxiety, suicidal ideation and suicide attempts within 10 years after surgery as compared to pre-surgery.

• Transgender adults who were affirmed in their gender identity—including access to medical care—were more likely to have sought out healthcare in the past year and reported better overall health.


• In a survey of surgeons who had collectively treated approximately 18,000-27,000 transgender patients over their careers, they reported only 62 patients expressed regret for their surgery, which is a regret rate of 0.2-0.3%.

• The reasons why patients regretted surgery included being misdiagnosed or changing their gender identity (42%), being rejected or alienated from their family and social circles (15%), and difficulty in their romantic relationships (11%).


• Among transgender adolescents and young adults, those who had not undergone chest surgery reported significantly higher levels of chest dysphoria. Additionally, self-reported regret was near zero.


• Using data from more than 27,000 transgender adults, the researchers found that those in US states with more structural transphobia (i.e., anti-trans laws/policies and transphobic attitudes) reported more severe psychological distress and were more likely to have experienced suicidal ideation in the past year.

Anti-Transgender Policies and Politics

The research in this section details the negative impacts of anti-transgender policies (e.g., conversion therapy), politics, and rhetoric on the well-being of transgender youth.

Borah L, Zebib L, Sanders HM, Lane M, Stroumsa D, Chung KC (2023). State Restrictions and Geographic Access to Gender-Affirming Care for Transgender Youth. JAMA

• Analyzed drive times to the nearest gender-affirming care clinic under optimal conditions (i.e., no traffic) compared to state bans on care. Only 1.4% of trans youth lived more than a 1-day drive from a clinic before state bans took effect, compared to 25.3% of trans youth once state restrictions were enacted.


• Analyzed data from the 2015 U.S. Transgender Survey and found that exposure to conversion therapy substantially increased the likelihood a transgender adolescent would attempt suicide (55% increase in risk) and run away (more than double the risk).

• These effects were largest when exposure to conversion therapy happened between 11-14 years of age.
Dhanani LY & Totton RR (2023). Have You Heard the News? The Effects of Exposure to News About Recent Transgender Legislation on Transgender Youth and Young Adults. *Sexuality Research and Social Policy*.

- This study examined the implications of consuming news related to proposed bans on medically necessary care for transgender people. Consuming more news related to anti-transgender legislation was associated with more persistent or unwanted thoughts and poorer physical health symptoms among transgender youth and adolescents.


- In a survey of more than 100 physicians, nurse practitioners, and physician’s assistants across the country, it was widely agreed that anti-transgender laws would have an adverse effect on the mental health of transgender youth and would worsen discrimination and societal exclusion.
- Providers described anti-transgender laws as unnecessary political influence in medical care and noted that this legislation goes against science and evidence-based practice.


- Transgender adults who were concerned about the enactment of state-level, anti-transgender policies had greater odds of depression, anxiety, and PTSD.


- More than 250 parents of transgender and gender diverse youth expressed fear that the proposed anti-transgender laws would worsen their child’s mental health, including increased depression, anxiety, and suicidal ideation.
- Parents emphasized that bans on medically necessary care are government overreach into private medical decisions.


- Approximately 45% of board-certified adolescent medicine providers practice in the jurisdiction of a proposed or enacted ban on treatment for gender dysphoria. This piece speaks to the need for supported public engagement, linkage of clinical services across state borders, institutional backing, and medical society advocacy to protect access to this care.


- Transmasculine and nonbinary youth described how anti-trans policies had negative impacts on their mental health, including depression, suicidality, and fear. They also expressed the structural impacts of these policies, including impacts on their personal safety and fear of losing access to health care.

- Using HRC’s State Equality Index measure, researchers found that LGBTQ youth in states with low LGBTQ inclusivity had higher odds of reporting their health as fair or poor and as experiencing poor mental health days.

### DETransition

*This section highlights research on individuals who decided to discontinue their gender transition (often referred to as detransitioners).*

Cavve BS, Bickendorf X, Ball J, et al. (2024). Reidentification With Birth-Registered Sex in a Western Australian Pediatric Gender Clinic Cohort. *JAMA Pediatrics*.

- In a study of nearly 550 youth who were referred to a pediatric gender clinic between 2014-2020, only two patients reidentified with their sex assigned at birth (i.e., no longer identified as transgender) after starting puberty delay medications. This represented 1.2% of all patients in the study who had ever initiated puberty suppression.


- In this study of 28 individuals who detransitioned, the majority of participants felt that medical interventions for transitioning were the right choice for them at the time and reported positive feelings about their gender transition. A majority also expressed support in autonomy to make healthcare decisions and an individualized approach to care.
- Of note, 60% of individuals in the study shifted from a binary transgender identity at the time of initiating their transition to a nonbinary identity as they continue to explore their gender.


- This was a study of 20 young people (aged 16-25) who discontinued their transition (socially, medically, and/or legally). Of these participants, 12 had undergone hormone therapy and only one participant decided to discontinue using this treatment.
- Participants discussed shifts in their views on gender, with many deciding to adopt other labels to describe their gender, such as agender, nonbinary, fluid, or not defining themselves with any one label.
- During transition, most participants mentioned feeling better in their bodies and/or experiencing less gender dysphoria.

### EXPERIENCES OF TRANSGENDER YOUTH

• Compared to adolescents in the general population, transgender adolescents spent similar amounts of time online and slightly less time on social media. Most of the time they spent online was for listening to music, watching movies/series, and communicating with friends.
• For transgender adolescents, their experience of gender was most influenced by puberty and distress around their body.


• In a study of transgender youth, their parents, and their healthcare providers, all three had similar ratings of the young person’s knowledge of gender-affirming care across a range of skills, including knowing and explaining their medical needs, knowing the name and dosage of their treatment, and knowing the long-term plan for hormone therapy.

CLINICAL GUIDELINES

The evidence-based clinical guidelines and standards of care that guide support and medical care for transgender people are detailed below.


UCSF Gender Affirming Health Program, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016.